Brief: Onxeo: Final Positive Data From DRIIV-1 Phase 1 Study Of AsiDNA

Valerio Therapeutics SA

28/05/2019 17:21

May 28 (Reuters) - ONXEO SA  C4X.PA :
    * ONXEO ANNOUNCES FINAL POSITIVE DATA FROM DRIIV-1 PHASE 1 STUDY OF ASIDNA™ IN ADVANCED
SOLID
TUMORS
    * PRIMARY SAFETY AND ACTIVITY ENDPOINTS MET
    * THE FULL RESULTS OF THE STUDY WILL BE PRESENTED AT UPCOMING INTERNATIONAL SCIENTIFIC
MEETINGS
    * FAVORABLE SAFETY PROFILE, MAXIMUM TOLERATED DOSE NOT REACHED, OPTIMAL ACTIVE DOSE
DETERMINED
    * ASIDNA™ INDUCED INTRATUMORAL ACTIVATION OF ITS DNA-PK TARGET, CONFIRMING ITS MECHANISM OF
ACTION

Source text for Eikon:  ID:nBw19jylsa 
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))